'Next Generation' Smallpox Vaccine Ordered by HHS

Modified vaccinia Ankara (MVA) smallpox vaccine worth $500 million soon will be added to the U.S. Strategic National Stockpile, following HHS' award of a contract for that amount to Bavarian Nordic A/S of Copenhagen, Denmark, for 20 million doses. This is a "next generation" vaccine intended for Americans with compromised immune systems in the event of a smallpox outbreak, HHS Secretary Mike Leavitt announced June 4.

"To protect ourselves from the remote but extremely grave threat of a deliberate release of smallpox virus, we need vaccines that can be safely given to all Americans, including individuals with weakened immune systems," he said. "Acquiring a stockpile of this new smallpox vaccine is a key step toward protecting even more members of the American public against a smallpox release." The vaccine contains a weakened form of the vaccinia virus that cannot replicate in humans, HHS said.

The contract was the first under Project BioShield to allow two types of pre-delivery payments, one under the Project BioShield Act of 2004 and the other under the Pandemic and All-Hazards Preparedness Act of 2006. "The use of these new authorities under the Pandemic and All-Hazards Preparedness Act further demonstrates our commitment to building improved partnerships with industry," Leavitt said.

Download Center

OH&S Digital Edition

  • OHS Magazine Digital Edition - June 2021

    June 2021

    Featuring:

    • PROTECTIVE APPAREL
      High-Visibility 101: Everything You Need to Know
    • FALL PROTECTION
      Seven Tips for How to Choose and Use SRLs
    • EMPLOYEE TESTING
      How to Keep Employees Safe in 2021
    • HEAT STRESS
      The Heat is Coming - Keep Your Cool Indoors and Out
    View This Issue